Why biotech stocks may be ready for a recovery
Biotech stocks have struggled in recent quarters as high interest rates take a toll on the capital-intensive sector. Jared Ablass, Vice President, Portfolio Research at TD Asset Management, speaks with MoneyTalk’s Greg Bonnell about how the sector could benefit once rates start to come down.